The Predictive Value of the Inflammatory Prognostic Index for Detecting No-Reflow in ST-Elevation Myocardial...

Area of Science:

• Cardiology
• Biomarkers
• Myocardial Infarction Research

Background:

• No-reflow (NR) is a critical complication in ST-segment elevation myocardial infarction (STEMI) patients post-primary percutaneous coronary intervention (pPCI).
• The Inflammatory Prognostic Index (IPI), calculated as neutrophil/lymphocyte ratio (NLR) multiplied by C-reactive protein/albumin ratio, is a novel marker with potential prognostic value.

Purpose of the Study:

• To investigate the association between the Inflammatory Prognostic Index (IPI) and the development of no-reflow (NR) in STEMI patients undergoing pPCI.
• To evaluate the predictive performance of IPI for NR compared to existing inflammatory markers.

Main Methods:

• A cohort study involving 1541 STEMI patients undergoing pPCI was conducted.
• Lasso regression was employed for variable selection, and a nomogram was developed using IPI to predict NR risk.
• Internal validation was performed using Bootstrap resampling to ensure model reproducibility.

Main Results:

• The Inflammatory Prognostic Index (IPI) was significantly higher in patients with no-reflow (NR) compared to those with reflow.
• IPI demonstrated superior discriminative ability for NR compared to systemic immune-inflammation index, NLR, and CRP/albumin ratio.
• The inclusion of IPI in a multivariable logistic regression model significantly improved the prediction of NR, with IPI being the most prominent variable.

Conclusions:

• This study establishes the first evidence linking the Inflammatory Prognostic Index (IPI) to no-reflow (NR) in STEMI patients undergoing pPCI.
• The IPI serves as a valuable and potent predictor for NR development in this patient population.
• A nomogram based on IPI offers a reliable tool for assessing NR risk in clinical practice.